Reactivation of p53 function in synovial sarcoma cells by inhibition of p53–HDM2 interaction
Authors:
- Pádraig D’arcyPDPádraig D’arcy
- Bríd Ann RyanBRBríd Ann Ryan
- Bertha BrodinBBBertha Brodin
- 1 March 2009
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 275 (2) , 285-292
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- The Oncoprotein SS18-SSX1 Promotes p53 Ubiquitination and Degradation by Enhancing HDM2 StabilityMolecular Cancer Research, 2008
- Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin‐3AInternational Journal of Cancer, 2007
- The Synovial Sarcoma–Associated SS18-SSX2 Fusion Protein Induces Epigenetic Gene (De)RegulationCancer Research, 2006
- Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL)Blood, 2006
- The synovial sarcoma translocation protein SYT-SSX2 recruits β-catenin to the nucleus and associates with it in an active complexOncogene, 2006
- Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myelomaBlood, 2005
- A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in HumansCell, 2004
- Live or let die: the cell's response to p53Nature Reviews Cancer, 2002
- Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53Nature, 1993
- The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivationCell, 1992